{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-016325","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2022-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.614482+00:00","generated_at":"2026-06-25T03:06:53.210726+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bone Biologics amends license with UCLA, deferring $8M diligence fee tied to future sales milestones","bullets":["Third Amendment extends development milestones; UCLA defers $8M diligence fee until first sale of licensed product.","$8M fee payable in tranches: $2M at $50M net sales, $2M at $100M, $4M at $200M cumulative net sales.","Obligation survives termination; assets cannot be transferred without assigning fee or paying within 10 days.","New milestones include initiating Phase I/II pilot study by Dec 31, 2024, and pegylated product milestones through 2030s.","Company must spend at least $1M per year on pre-clinical/clinical development until Phase III completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-016325","json":"https://secwatch.observer/filing/0001493152-22-016325.json","markdown":"https://secwatch.observer/filing/0001493152-22-016325.md","text":"https://secwatch.observer/filing/0001493152-22-016325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315222016325/0001493152-22-016325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315222016325/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:06:53.210726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}